On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Investigational HIV vaccine regimen shows encouraging results in non-human primates

Investigational HIV vaccine regimen shows encouraging results in non-human primates Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell...

HIV investigators at Harvard, J&J see promise in early-stage vaccine

A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.

Kiadis banks $36M in a Euro IPO to fund its stem cell R&D

Dutch drug developer Kiadis Pharma pulled in €32.7 million ($36.3 million) in a European IPO, raising cash to develop a pair of stem cell treatments.

Fred Hutch's Gilliland optimistic about cancer cures; Report: Biosims market to jump to $20B;

@FierceBiotech: ICYMI yesterday: Baxalta sets sail with blockbuster ambitions for its growing pipeline. Article | Follow @FierceBiotech @JohnCFierce: Trending yesterday: Whittled down to biotech...

Ex-Pharmacyclics team raises $33.5M for checkpoint drug

Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals.

Gilead takes a $125M FDA shortcut with its latest HIV combo

Last year, Gilead Sciences paid $125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment for approval and lining up for a truncated regulatory process.

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)

– Gilead's Third TAF-based Filing, Submitted with Priority Review Voucher – FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 1, 2015-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced...

A booming Celgene grabs Merck's abandoned campus in New Jersey

Fresh off a landmark $1 billion deal to buy into Juno's immuno-oncology pipeline, fast-growing Celgene has inked another contract to buy up Merck's sprawling old campus in Summit, NJ.

Four years after buyout, Pfizer spins Icagen ion channel platform back out

Four years ago, Pfizer spent $56 million to bag Icagen and add its ion channel R&D platform and pipeline in North Carolina with its pain drug development arm in the U.K. But yesterday the pharma giant spun the platform back out to a small contract research group in Cambridge, MA, called XRPro Sciences, which will now combine its operations into an expanded research services operation that will cater to the biopharma industry.